Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
Multiplex Assay Kit for Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay)
DGSX; OCI5; SDYS; SGB; SGBS1; MXR7; Glypican Proteoglycan 3; GTR2-2; Intestinal protein OCI-5; Secreted glypican-3
(Note: Up to 8-plex in one testing reaction)
- Product No.LMA971Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- Sample Typeserum, plasma, tissue homogenates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.01-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.003 ng/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 427
US$ 443
US$ 468
US$ 501
US$ 534
US$ 583
US$ 657
Result
For more details, please contact local distributors! US$ 821 Add to Price Calculator
Specificity
This assay has high sensitivity and excellent specificity for detection of Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 86-101 | 91 |
EDTA plasma(n=5) | 95-102 | 98 |
heparin plasma(n=5) | 92-99 | 96 |
sodium citrate plasma(n=5) | 79-93 | 82 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 98-105% | 96-105% | 78-101% | 94-101% |
EDTA plasma(n=5) | 94-105% | 83-103% | 87-99% | 85-104% |
heparin plasma(n=5) | 93-102% | 90-105% | 89-96% | 85-104% |
sodium citrate plasma(n=5) | 84-93% | 82-89% | 83-97% | 78-92% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:GPC3) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Nature and Science | Diagnostic Role of Serum Glypican-3 as a Tumor Marker for Hepatocellular Carcinoma Sciencepub:10043238 |
Journal of Applied Pharmaceutical Science | Cytotoxic effects of antiglypican-3 against HepG2 cell line Ebscohost: Source |
Asian Pacific Journal of Cancer Prevention | Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients? Pubmed: 24460300 |
Clin Biochem. | Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis Pubmed: 24362268 |
Science and Nature | Diagnostic Role of Serum Glypican-3 as Hepatocellular Carcinoma Zolcat: Source |
Alexandria Journal of Medicine | Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis ScienceDirect: S2090506814000062 |
J Egypt Natl Canc Inst. | Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients. Pubmed:24841158 |
European Journal of Pharmacology | Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma Pubmed:25449037 |
Hepatobiliary Pancreat Dis Int | Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern abstract:abstract4525.shtml |
Clinical and Molecular Hepatology | Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis pmc:articles |
Wiley | Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment pubmed:28621802 |
Biomedicine & Pharmacotherapy | Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 and Pubmed:29669302 |
Journal of Cancer and Clinical Oncology | Development and Validation of a Two-Site Immunoradiometric assay for Glypican-3 in plasma: Implication in Diagnosis of Hepatocellular Carcinoma Researchgate:Source |
Turkish journal of oncology | Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma 10.5505:tjo.2018.1742 |
Intensive Care Medicine Experimental | Elevated plasma glypicans are associated with organ failure in patients with infection Pubmed: 30618011 |
VALUE OF SERUM GLYPICAN 3 AS A PREDICTIVE TOOL FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) | |
ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C |
Life Sci | Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and … Pubmed:35640776 |
Catalog No. | Related products for research use of Rattus norvegicus (Rat) Organism species | Applications (RESEARCH USE ONLY!) |
RPA971Ra01 | Recombinant Glypican 3 (GPC3) | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA971Ra01 | Polyclonal Antibody to Glypican 3 (GPC3) | WB; IHC; ICC; IP. |
MAA971Ra21 | Monoclonal Antibody to Glypican 3 (GPC3) | WB; IHC; ICC; IP. |
SEA971Ra | ELISA Kit for Glypican 3 (GPC3) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA971Ra | Multiplex Assay Kit for Glypican 3 (GPC3) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |